Skip to main content
Skip to main content
NIVF logo

NewGenIvf Group Limited (NIVF) Stock Analysis

Educational signal · not a buy or sell recommendation · How to read this

$1.11 $0.00 (0.00%)
P/E Ratio: 0.01| Vol: 88.0K| Target: $900.00 (estimate, not advice)| 52-wk range: $1.02 – $1539.00

P/E 0.01 means the share price is 0.01 times one year of earnings per share; the S&P 500 usually sits near 20-25. Beta 0.03: the stock has moved about 97% less than the S&P 500.

Data from FMP · Methodology

For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 31, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR

Quick Answer

NewGenIvf Group Limited (NIVF) trades at $1.11. NewGenIVF Group Ltd. is an assisted reproductive services provider based in Bangkok, Thailand. Sector: Healthcare.

Price as of Sep 11, 2026 · Last analyzed: May 31, 2026
NewGenIVF Group Ltd. is an assisted reproductive services provider based in Bangkok, Thailand. The company focuses on providing fertility treatments, including in-vitro fertilization, egg donation, and surrogacy services, to help individuals and couples build families.

NIVF stock analysis for 2026: The stored analyst price target for NewGenIvf Group Limited is $900.00; its date is unknown, so no upside or downside is derived from it against the current price of $1.11. Key factors: analyst coverage, company fundamentals.

Watch the NIVF film Every key number, told as a short cinematic story — just press play. ~2 min

NewGenIvf Group Limited (NIVF) Healthcare & Pipeline Overview

CEOWing Fung Siu
Employees87
HeadquartersBangkok, TH
IPO Year2022

NewGenIVF Group Ltd., headquartered in Bangkok, Thailand, operates as an assisted reproductive services provider, offering in-vitro fertilization, egg donation, and surrogacy services.

Data Provenance | Financial Data Quantitative Analysis Analysis: May 31, 2026

What Is the Investment Thesis for NIVF?

AI-written as of May 31, 2026 — figures and tone reflect the data available then, not today's score.

NewGenIVF Group Ltd. presents a focused investment opportunity within the assisted reproductive services sector. With a low Beta of 0.03, the stock exhibits minimal volatility relative to the market. Key value drivers include the growing demand for fertility treatments and the company's comprehensive service offerings, encompassing IVF, egg donation, and surrogacy. Growth catalysts include expanding the company's geographic reach and developing strategic partnerships. Potential risks include regulatory changes in the healthcare sector and competition from other fertility clinics. The company's P/E ratio of 0.01 may indicate undervaluation, warranting further investigation into its financial health and growth prospects.

Based on FMP financials and quantitative analysis

NIVF Key Highlights

AI-written as of May 31, 2026 — figures and tone reflect the data available then, not today's score.

Profit Margin of 338.2% indicates high profitability, potentially driven by efficient cost management or premium pricing strategies.

  • Gross Margin of 23.7% suggests room for improvement in cost of goods sold or pricing strategies to enhance profitability.
  • P/E Ratio of 0.01 may indicate undervaluation relative to earnings, potentially offering an attractive entry point for investors.
  • Beta of 0.03 suggests low volatility compared to the broader market, making it a potentially stable investment.
  • No Dividend Yield reflects a strategy of reinvesting earnings for growth, which may appeal to investors seeking capital appreciation.

Who Are NIVF's Competitors?

NIVF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

Company Price Change Market Cap MoonshotScore
HCA HCA Healthcare, Inc. $426.98 +1.37% $92.4B 815-pillar
THC Tenet Healthcare Corporation $263.46 -2.09% $21.2B 885-pillar
SOLV Solventum Corporation $87.80 +0.17% $15.2B 595-pillar
EHC Encompass Health Corporation $121.04 -0.40% $12.0B 895-pillar
FMS Fresenius Medical Care AG & Co. KGaA $22.23 -0.45% $11.9B 825-pillar
DVA DaVita Inc. $181.33 -0.92% $11.6B 745-pillar
UHS Universal Health Services, Inc. $172.72 -1.74% $10.5B 935-pillar
ENSG The Ensign Group, Inc. $172.79 +0.60% $10.1B 745-pillar

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are NIVF's Key Strengths?

High profit margin of 338.2%.

  • Comprehensive range of assisted reproductive services.
  • Experienced team of fertility specialists.
  • Location in Bangkok, a popular destination for medical tourism.

What Are NIVF's Weaknesses?

Relatively small size with 76 employees.

  • Limited geographic presence, primarily in Bangkok.
  • Gross margin of 23.7% could be improved.
  • No dividend yield, which may deter some investors.

What Could Drive NIVF Stock Higher?

Expansion into new geographic markets, particularly in regions with growing demand for fertility treatments.

  • Strategic partnerships with hospitals, clinics, and other healthcare providers to expand reach and referral network.
  • Implementation of advanced reproductive technologies, such as preimplantation genetic testing (PGT) and time-lapse imaging, to improve treatment outcomes (within 1-2 years).
  • Diversification of service offerings to include related areas such as genetic counseling and wellness programs.

What Are the Key Risks for NIVF?

Financial-distress signal — its Altman Z-Score of 1.71 sits in the distress zone (elevated bankruptcy risk).

  • Increased competition from other fertility clinics and ART providers.
  • Regulatory changes in the healthcare sector that could impact the company's operations.
  • Economic downturns that could reduce demand for fertility treatments.
  • Ethical and social concerns surrounding assisted reproductive technologies.
  • Dependence on a relatively small team of 76 employees.

What Are the Growth Opportunities for NIVF?

  • Geographic Expansion: Expanding operations into new geographic markets, particularly in regions with growing demand for fertility treatments, represents a significant growth opportunity. The global fertility services market is projected to reach $36 billion by 2026, offering ample room for expansion. Timeline: Within the next 3-5 years, NewGenIVF could establish new clinics or partnerships in key markets, leveraging its expertise and service offerings. Competitive Advantage: By focusing on underserved markets and offering specialized treatments, NewGenIVF can differentiate itself from competitors and capture market share.
  • Strategic Partnerships: Forming strategic partnerships with hospitals, clinics, and other healthcare providers can expand NewGenIVF's reach and referral network. Collaborating with research institutions and universities can also enhance its technological capabilities and service offerings. Timeline: Over the next 2-3 years, NewGenIVF could forge partnerships with key players in the healthcare ecosystem, creating synergies and expanding its market presence. Competitive Advantage: By leveraging the resources and expertise of its partners, NewGenIVF can offer a more comprehensive and integrated suite of services, attracting a wider range of clients.
  • Technological Advancements: Investing in advanced reproductive technologies, such as preimplantation genetic testing (PGT), time-lapse imaging, and artificial intelligence (AI)-assisted embryo selection, can improve treatment outcomes and attract clients seeking the latest innovations. The market for reproductive technologies is growing rapidly, driven by the increasing demand for fertility treatments and the desire for higher success rates. Timeline: Within the next 1-2 years, NewGenIVF could implement new technologies in its clinics, enhancing its service offerings and improving patient outcomes. Competitive Advantage: By staying at the forefront of technological advancements, NewGenIVF can differentiate itself from competitors and attract clients seeking the most advanced fertility treatments.
  • Service Diversification: Diversifying its service offerings to include related areas such as genetic counseling, reproductive endocrinology, and wellness programs can enhance NewGenIVF's value proposition and attract a broader range of clients. The market for complementary services is growing, as individuals and couples seek holistic support throughout their fertility journey. Timeline: Over the next 2-3 years, NewGenIVF could expand its service offerings to include complementary services, creating a more comprehensive and integrated patient experience. Competitive Advantage: By offering a one-stop-shop for fertility-related services, NewGenIVF can attract clients seeking convenience and comprehensive care.
  • Marketing and Branding: Enhancing its marketing and branding efforts to increase awareness and attract new clients represents a significant growth opportunity. The fertility services market is competitive, and effective marketing is essential for attracting clients and building brand recognition. Timeline: Within the next 6-12 months, NewGenIVF could launch new marketing campaigns, revamp its website, and increase its presence on social media, enhancing its brand visibility and attracting new clients. Competitive Advantage: By developing a strong brand identity and effectively communicating its value proposition, NewGenIVF can differentiate itself from competitors and attract clients seeking high-quality fertility treatments.

What Are NIVF's Competitive Advantages?

  • Specialized expertise in assisted reproductive technologies.
  • Established reputation and brand recognition in the Bangkok area.
  • Comprehensive service offerings, including IVF, egg donation, and surrogacy.
  • Focus on personalized care and patient support.

What Does NIVF Do?

NewGenIVF Group Ltd. is an assisted reproductive services provider dedicated to offering fertility treatments to individuals and couples seeking to build families. Headquartered in Bangkok, Thailand, the company specializes in a range of services, including in-vitro fertilization (IVF), egg donation, surrogacy, and ancillary caring services. NewGenIVF aims to provide comprehensive support throughout the fertility journey, addressing the diverse needs of its clients. The company's core offering is in-vitro fertilization treatment, encompassing both traditional IVF methods and egg donation programs. These services are designed to assist individuals and couples facing challenges with natural conception. Additionally, NewGenIVF provides surrogacy services, offering a pathway to parenthood for those who are unable to carry a pregnancy themselves. Ancillary caring services complement the core treatments, ensuring that clients receive holistic support throughout the process. With a focus on personalized care and advanced reproductive technologies, NewGenIVF Group Ltd. strives to be a leading provider in the assisted reproductive services market, helping individuals and couples achieve their dreams of starting a family.

What Products and Services Does NIVF Offer?

  • Provides in-vitro fertilization (IVF) treatments to individuals and couples.
  • Offers egg donation services for those who require donor eggs.
  • Facilitates surrogacy arrangements for individuals or couples unable to carry a pregnancy.
  • Offers ancillary caring services to support clients throughout the fertility treatment process.
  • Aims to fulfill the dreams of building families through assisted reproductive technologies.
  • Operates fertility clinics in Bangkok, Thailand.

How Does NIVF Make Money?

  • Generates revenue by providing IVF treatments, egg donation, and surrogacy services.
  • Charges fees for ancillary caring services, such as counseling and support programs.
  • May offer package deals or financing options to make treatments more accessible.
  • Focuses on providing personalized care and advanced reproductive technologies to attract clients.

What Industry Does NIVF Operate In?

NewGenIVF Group Ltd. operates within the assisted reproductive technology (ART) industry, a segment of the healthcare sector experiencing steady growth due to increasing infertility rates, advancements in medical technology, and changing social norms. The market is competitive, with numerous fertility clinics and ART providers vying for market share. Key trends include the rising demand for IVF, egg donation, and surrogacy services, as well as the increasing adoption of advanced technologies such as preimplantation genetic testing (PGT) and time-lapse imaging. NewGenIVF's focus on comprehensive fertility treatments positions it to capitalize on these trends, although it faces competition from established players and emerging clinics.

Who Are NIVF's Key Customers?

  • Individuals and couples struggling with infertility.
  • Individuals or couples who are unable to conceive naturally.
  • Same-sex couples seeking to have children.
  • Individuals or couples who require egg donation or surrogacy services.
Model self-rating on this text: 65% (not a measure of the evidence) Updated: May 31, 2026

Research confidence

Medium 49/100

Enough evidence to be useful, with gaps worth knowing about.

  • Scoring coverage unknown
  • Price is current
  • Latest filing 164 days ago
  • Covered by analysts
  • This is an unknown, not an operating company

MoonshotScore History

Recorded daily since 2026-08-23 · 20 snapshots

2026-08-23 43
2026-08-27 43
2026-08-31 43
2026-09-04 43
2026-09-08 43
2026-09-11 43

What changed?

The score has stayed at 43.

Over the same 19 days the stock moved +90.9%.

ROE 33%

Key Financial Metrics

Return on equity for NewGenIvf Group Limited stands at 32.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 28.0%, showing how much profit it generates from its asset base. NIVF trades at a trailing price-to-earnings ratio of 0.01, below the Healthcare sector average of ~21.50x. A current ratio of 3.12 indicates the company holds enough short-term assets to cover its near-term obligations.

NIVF Revenue & Earnings Trend

In Q4 FY2025, NIVF generated $1.4M in top-line revenue, marking a sequential increase of 11.1%. The company recorded a net loss of $7.7M, with diluted EPS of $-117.36. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this unknown Healthcare company. Across the four most recent quarters, NIVF averaged $21.73 in diluted EPS.

Company Profile

NewGenIvf Group Limited operates in the Medical - Care Facilities industry within the Healthcare sector. It is headquartered in Bangkok, TH. The company is led by CEO Wing Fung Siu. NIVF has traded publicly since 2022.

F-Score 5/9

Financial Health

NewGenIvf Group Limited's Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 1.71 places it in the distress zone, a signal of elevated financial risk.

FY2026 est

Forward Outlook

Wall Street analysts project NewGenIvf Group Limited revenue of about $65.1M for fiscal 2026, with EPS near $42.66.

Net buying

Insider Activity

Over the past six months, NewGenIvf Group Limited insiders filed 14 SEC Form 4 transactions — 2 sales and 12 purchases. On net that is roughly 969K shares acquired (about $75K) — insiders putting money in tends to read as conviction.

NIVF Financials

Fundamental Snapshot

Revenue Growth (FY)
-13.0%
EPS Growth (FY)
+175.3%
Free Cash Flow Growth (FY)
-100.5%
P/E (TTM)
0.01
Return on Equity (TTM)
+32.7%
Current Ratio
3.1

Based on FMP financials and quantitative analysis · FY 2025

Bull Case vs Bear Case

Bull Case

  • High profit margin of 338.2%.
  • Comprehensive range of assisted reproductive services.
  • Experienced team of fertility specialists.
  • Location in Bangkok, a popular destination for medical tourism.

Bear Case

  • Relatively small size with 76 employees.
  • Limited geographic presence, primarily in Bangkok.
  • Gross margin of 23.7% could be improved.
  • No dividend yield, which may deter some investors.

AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · May 2026

Recent Quarterly Results

Quarter Revenue Net Income EPS
Q4 FY2025 $1M -$8M -$117.36
Q3 FY2025 $1M $17M $257.40
Q4 FY2024 $1M -$108,000 -$41.37
Q3 FY2024 $1M -$19,857 -$11.76

Q4 FY2025 · filed 31 Mar 2026 · SEC EDGAR →

Based on FMP financials and quantitative analysis

NIVF Latest News

NIVF Analyst Consensus

Consensus Rating

Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for NIVF.

Price Targets

Consensus target: $900.00

NIVF MoonshotScore

MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for NIVF; grades run from A+ (80-100) to F (below 30).

Leadership: Wing Fung Siu

CEO

Wing Fung Siu serves as the CEO of NewGenIVF Group Ltd., managing a team of 76 employees. However, as CEO, Wing Fung Siu is responsible for overseeing the company's strategic direction, operational performance, and financial results. The CEO plays a crucial role in driving growth, fostering innovation, and ensuring that NewGenIVF Group Ltd. remains a leading provider of assisted reproductive services.

Track Record: Due to limited information on Wing Fung Siu's specific achievements and strategic decisions at NewGenIVF Group Ltd., it is challenging to assess their track record comprehensively. However, the company's high profit margin of 338.2% suggests effective management and operational efficiency under their leadership. Further information on key milestones and strategic initiatives would be needed to provide a more detailed evaluation of their performance.

What Investors Ask About NewGenIvf Group Limited (NIVF) — Healthcare

Is NIVF a good stock?

Stock Expert AI does not rate NIVF buy, sell or hold. NewGenIvf Group Limited has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns, what the price assumes, and what would prove you wrong.

What do analysts say about NIVF stock?

There is currently no available analyst coverage or consensus on NewGenIvf Group Limited (NIVF) stock. Given the company's small market capitalization and limited trading history, it may not be widely followed by analysts. Key valuation metrics to consider include the company's P/E ratio of 0.01 and profit margin of 338.2%.

What are the key factors to evaluate for NIVF?

Evaluate NIVF on fundamentals, analyst consensus, and risk factors. P/E: 0.01x vs the S&P 500's ~20-25x. With a low Beta of 0.03, the stock exhibits minimal volatility relative to the market. Not financial advice.

How frequently does NIVF data refresh on this page?

NIVF's price was last updated on Sep 11, 2026 and refreshes on page view during U.S. market hours; the quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 calculations are scheduled daily at 10:15 UTC; the score's own date shows its last successful run.

What has driven NIVF's recent stock price performance?

NewGenIvf Group Limited (NIVF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: High profit margin of 338.2%. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider NIVF overvalued or undervalued right now?

NewGenIvf Group Limited (NIVF) trades at 0.01x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

Can I buy fractional shares of NIVF?

Yes, most major brokerages offer fractional shares of NewGenIvf Group Limited (NIVF) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.

How can I track NIVF's earnings and financial reports?

NewGenIvf Group Limited (NIVF) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for NIVF earnings announcements.

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources

Price as of Analysis updated

MoonshotScore is not published for this security.

Data Sources & Methodology
Market data powered by Financial Modeling Prep & Yahoo Finance. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.
Data provided as-is for educational purposes. Not financial advice. Methodology

Data provided for informational purposes only.

Analysis Notes
  • Limited information available on the company's history and operations.
  • Lack of analyst coverage and consensus estimates.
  • Small market capitalization and limited trading history.
Data Sources
Financial Modeling Prep (FMP)Stock Expert AI proprietary analysis

More Stocks We Cover